The Dutch pharmaceutical market is anticipated to show moderate growth with a CAGR of 5.8% during the forecast period.
The COVID-19 pandemic had a significant impact on the market in its early phase due to various lockdown regulations that were imposed. For instance, according to an article published by PubMed Central in January 2021, a cross-sectional study was performed, which showed that there was a considerable impact of the COVID-19 pandemic on both logistic procedures and services in the pharmacies of the Netherlands. The reduction in such services meant fewer pharmaceutical sales. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, post pandemic the market studied is expected to have stable growth during the forecast period of the study.
The presence of world-class research institutes, a highly educated workforce, an excellent healthcare system, and an innovation-friendly government, combined with a central location, makes the country an ideal base for biopharmaceutical operations. Healthcare and medical spending have increased over the past few years, reflecting strong potential for new medicine development, infrastructure building, and new entry/expansion opportunities. At the same time, the government is taking various initiatives to lower the prices of pharmaceutical products, which is expected to have adverse effects on the profitability of pharmaceutical companies. The Netherlands is expected soon negotiate lowering drug prices with pharmaceutical companies.
As per the data published by the Dutch Cancer Society (KWF), in 2021, cancer was the leading cause of death in the Netherlands. According to the same data, in 2021, an estimated 44,996 persons died of cancer, out of which 24,266 were men, and 20,730 were women. Furthermore, according to the data published by the World Bank, in 2022, the prevalence of diabetes as a percentage of the population aged between 20 and 79 was 4.5% in the Netherlands in 2021. Hence with the increasing burden of various diseases, it is expected that there will be steady growth in the market.
Therefore, owing to the aforementioned factors, the market is anticipated to witness growth over the forecast period. However, the high failure rate and developing cost of new products are likely to impede the growth of the market.
Furthermore, according to the European Survey of Cardiovascular Disease conducted by Daiichi Sankyo in July 2022, a survey was conducted in European nations which showed that 82.8% respondents of Netherlands are aware of chest tightening, and 66.7% of the respondents are aware of heart palpitations. The survey also showed that 51% of the respondents made an appointment with healthcare professionals to seek advice about cardiovascular disease symptoms.
Moreover, increasing product approvals and key developments by market players are also enhancing segment growth. For instance, in July 2021, European Medicines Agency (EMA) approved Verquvo throughout the European Union. Verquvo is a medicine used to treat adults with long-term heart failure with reduced ejection fraction who recently received intravenous (into the vein) treatment because of the worsening of their symptoms. Furthermore, in September 2021, Oxitope Pharma BV started its business in the Netherlands as a biopharmaceutical start-up dedicated to discovering and developing antibody-based medicines for treating diseases caused by oxidative stress.
Thus, owing to the increasing disease burden, product approvals, coupled with increasing awareness among people about cardiovascular diseases and better health guidelines, the segment is expected to experience growth in the future.
The increasing prevalence of infectious diseases in the country is a major factor driving the growth of the segment, as it means more use of prescription-based drugs. For instance, according to an article published by Eurosurveillance in June 2022, in the Netherlands, monkeypox was classified as a group A notifiable disease, which means that suspected and confirmed cases of monkeypox should be immediately notified to the public health services. As of May 2022, 31 monkeypox cases were laboratory-confirmed by PCR in the country.
Moreover, new prescription-based product launches in the country are also enhancing the segment's growth. For instance, in November 2022, Sanofi announced that its prescription drug Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD) had received marketing authorization from European Commission (EC). Furthermore, in September 2022, EMA issued a marketing authorization for Tezspire that is valid throughout the European Union. Tezspire is a prescription-based drug for the treatment of severe asthma.
Hence, due to factors such as the increasing prevalence of infectious diseases and rising product launches by key market players, the prescription segment is expected to experience growth.
This product will be delivered within 2 business days.
The COVID-19 pandemic had a significant impact on the market in its early phase due to various lockdown regulations that were imposed. For instance, according to an article published by PubMed Central in January 2021, a cross-sectional study was performed, which showed that there was a considerable impact of the COVID-19 pandemic on both logistic procedures and services in the pharmacies of the Netherlands. The reduction in such services meant fewer pharmaceutical sales. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, post pandemic the market studied is expected to have stable growth during the forecast period of the study.
The presence of world-class research institutes, a highly educated workforce, an excellent healthcare system, and an innovation-friendly government, combined with a central location, makes the country an ideal base for biopharmaceutical operations. Healthcare and medical spending have increased over the past few years, reflecting strong potential for new medicine development, infrastructure building, and new entry/expansion opportunities. At the same time, the government is taking various initiatives to lower the prices of pharmaceutical products, which is expected to have adverse effects on the profitability of pharmaceutical companies. The Netherlands is expected soon negotiate lowering drug prices with pharmaceutical companies.
As per the data published by the Dutch Cancer Society (KWF), in 2021, cancer was the leading cause of death in the Netherlands. According to the same data, in 2021, an estimated 44,996 persons died of cancer, out of which 24,266 were men, and 20,730 were women. Furthermore, according to the data published by the World Bank, in 2022, the prevalence of diabetes as a percentage of the population aged between 20 and 79 was 4.5% in the Netherlands in 2021. Hence with the increasing burden of various diseases, it is expected that there will be steady growth in the market.
Therefore, owing to the aforementioned factors, the market is anticipated to witness growth over the forecast period. However, the high failure rate and developing cost of new products are likely to impede the growth of the market.
Netherlands Pharmaceutical Market Trends
Cardiovascular Segment is Expected to Hold a Significant Market Share over the Forecast Period
Increased cardiovascular diseases are one of the key factors for the growth of the market. According to an article published by the Health Policy Partnership in 2021, in the Netherlands, heart attack and stroke are significant health concerns among the population. It is estimated that over 740,000 people are living with coronary heart disease (CHD), which includes heart attack, and more than 216,000 people had a stroke in 2021, and these numbers are rising. The article also stated that the direct cost of CHD and cerebrovascular disease to the Dutch healthcare system amounts to EUR 2.1 billion (USD 2.38 billion) per year.Furthermore, according to the European Survey of Cardiovascular Disease conducted by Daiichi Sankyo in July 2022, a survey was conducted in European nations which showed that 82.8% respondents of Netherlands are aware of chest tightening, and 66.7% of the respondents are aware of heart palpitations. The survey also showed that 51% of the respondents made an appointment with healthcare professionals to seek advice about cardiovascular disease symptoms.
Moreover, increasing product approvals and key developments by market players are also enhancing segment growth. For instance, in July 2021, European Medicines Agency (EMA) approved Verquvo throughout the European Union. Verquvo is a medicine used to treat adults with long-term heart failure with reduced ejection fraction who recently received intravenous (into the vein) treatment because of the worsening of their symptoms. Furthermore, in September 2021, Oxitope Pharma BV started its business in the Netherlands as a biopharmaceutical start-up dedicated to discovering and developing antibody-based medicines for treating diseases caused by oxidative stress.
Thus, owing to the increasing disease burden, product approvals, coupled with increasing awareness among people about cardiovascular diseases and better health guidelines, the segment is expected to experience growth in the future.
Prescription Segment is Expected to Witness Significant Growth Over the Forecast Period
The major factors driving the growth of the segment are the increasing prevalence of chronic and infectious diseases, the rising research and development activities by major players for new prescription-based drugs, and new product launches by key market players.The increasing prevalence of infectious diseases in the country is a major factor driving the growth of the segment, as it means more use of prescription-based drugs. For instance, according to an article published by Eurosurveillance in June 2022, in the Netherlands, monkeypox was classified as a group A notifiable disease, which means that suspected and confirmed cases of monkeypox should be immediately notified to the public health services. As of May 2022, 31 monkeypox cases were laboratory-confirmed by PCR in the country.
Moreover, new prescription-based product launches in the country are also enhancing the segment's growth. For instance, in November 2022, Sanofi announced that its prescription drug Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD) had received marketing authorization from European Commission (EC). Furthermore, in September 2022, EMA issued a marketing authorization for Tezspire that is valid throughout the European Union. Tezspire is a prescription-based drug for the treatment of severe asthma.
Hence, due to factors such as the increasing prevalence of infectious diseases and rising product launches by key market players, the prescription segment is expected to experience growth.
Netherlands Pharmaceutical Market Competitor Analysis
The Dutch pharmaceutical market is moderately fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the key companies which are currently dominating the market are Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma, AstraZeneca PLC, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Novartis AG, and Pfizer Inc.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE AND COMPANY PROFILES
Methodology
LOADING...
